{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:20:16Z","timestamp":1790806816380,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T00:00:00Z","timestamp":1418515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1007\/s00417-014-2867-0","type":"journal-article","created":{"date-parts":[[2014,12,13]],"date-time":"2014-12-13T03:07:13Z","timestamp":1418440033000},"page":"1677-1683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity \u2014 27 month follow-up results from Turkey"],"prefix":"10.1007","volume":"253","author":[{"given":"Huseyin","family":"Yetik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Gunay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarkis","family":"Sirop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziya","family":"Salihoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,14]]},"reference":[{"issue":"9070","key":"2867_CR1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0140-6736(97)01107-0","volume":"350","author":"C Gilbert","year":"1997","unstructured":"Gilbert C, Rahi J, Eckstein M, O\u2019Sullivan J, Foster A (1997) Retinopathy of prematurity in middle-income countries. Lancet 350(9070):12\u201314","journal-title":"Lancet"},{"issue":"4","key":"2867_CR2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1001\/archopht.1988.01060130517027","volume":"106","author":"Cryotherapy for Retinopathy of Prematurity Cooperative Group","year":"1988","unstructured":"Cryotherapy for Retinopathy of Prematurity Cooperative Group (1988) Multicenter trial of cryotherapy for retinopathy of prematurity: preliminary results. Arch Ophthalmol 106(4):471\u2013479","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"2867_CR3","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.121.12.1684","volume":"121","author":"Early Treatment for Retinopathy of Prematurity Cooperative Group","year":"2003","unstructured":"Early Treatment for Retinopathy of Prematurity Cooperative Group (2003) Revised indications for the treatment of retinopathy of prematurity:results of the early treatment for retinopathy of prematurity randomized trial. Arch Ophthalmol 121(12):1684\u20131694","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"2867_CR4","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.123.7.991","volume":"123","author":"International Committee for the Classification of Retinopathy of Prematurity","year":"2005","unstructured":"International Committee for the Classification of Retinopathy of Prematurity (2005) The International Classification of Retinopathy of Prematurity revisited. Arch Ophthalmol 123(7):991\u2013999","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"2867_CR5","first-page":"54","volume":"80","author":"H Morizane","year":"1976","unstructured":"Morizane H (1976) Initial sign and clinical course of the most severe form of acute proliferative retrolental fibroplasias (type 1) [in Japanese]. Nippon Ganka Gakkai Zasshi 80(1):54\u201361","journal-title":"Nippon Ganka Gakkai Zasshi"},{"issue":"6","key":"2867_CR6","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1395-3907.2003.00171.x","volume":"81","author":"M O\u2019Keefe","year":"2003","unstructured":"O\u2019Keefe M, Lanigan B, Long VW (2003) Outcome of zone I retinopathy of prematurity. Acta Ophthalmol Scand 81(6):614\u2013616","journal-title":"Acta Ophthalmol Scand"},{"issue":"1","key":"2867_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0161-6420(00)00436-X","volume":"108","author":"CB Onofrey","year":"2001","unstructured":"Onofrey CB, Feuer WJ, Flynn JT (2001) The outcome of retinopathy of prematurity: screening for retinopathy of prematurity using an outcome predictive program. Ophthalmology 108(1):27\u201335","journal-title":"Ophthalmology"},{"issue":"5","key":"2867_CR8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10384-004-0216-2","volume":"49","author":"Y Hatsukawa","year":"2005","unstructured":"Hatsukawa Y, Ueki N, Yamagishi T, Kiytajima H (2005) The effect of early treatment at the initial stage 3 moderate phase of retinopathy of prematurity on severe retinal changes. Jpn J Ophthalmol 49(5):391\u2013396","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"2867_CR9","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ajo.2010.10.007","volume":"151","author":"S Jalali","year":"2011","unstructured":"Jalali S, Kesarwani S, Hussain A (2011) Outcomes of a protocol-based management of zone 1 retinopathy of prematurity: the Indian Twin Cities ROP Screening Program Report Number 2. Am J Ophthalmol 151(4):719\u2013724","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"2867_CR10","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ajo.2008.05.010","volume":"146","author":"S Yuka","year":"2008","unstructured":"Yuka S, Fujino T, Hatsukawa Y (2008) Progression and timing of treatment of zone 1 retinopathy of prematurity. Am J Ophthalmol 146(3):369\u2013374","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"2867_CR11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.iae.0000244285.79004.e6","volume":"26","author":"A Kychenthal","year":"2006","unstructured":"Kychenthal A, Dorta P, Katz X (2006) Zone 1 retinopathy of prematurity. Retina 26(7):11\u201315","journal-title":"Retina"},{"issue":"7","key":"2867_CR12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.oftal.2011.05.008","volume":"86","author":"I Gonz\u00e1lez Viejo","year":"2011","unstructured":"Gonz\u00e1lez Viejo I, Ferrer Novella C, Pueyo RV (2011) Use of anti-VEGF (anti-vascular endothelial growth factor) in retinopathy of prematurity (ROP). Arch Soc Esp Oftalmol 86(7):207\u2013208","journal-title":"Arch Soc Esp Oftalmol."},{"issue":"10","key":"2867_CR13","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.earlhumdev.2009.08.026","volume":"85","author":"C Romagnoli","year":"2009","unstructured":"Romagnoli C (2009) Risk factors and growth factors in ROP. Early Hum Dev 85(10):79\u201382","journal-title":"Early Hum Dev."},{"key":"2867_CR14","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1038\/nm1095-1024","volume":"1","author":"T Alon","year":"1995","unstructured":"Alon T, Hemo I, Itin A et al (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1:1024\u20131028","journal-title":"Nat Med"},{"issue":"1","key":"2867_CR15","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ophtha.2010.04.018","volume":"118","author":"WC Wu","year":"2011","unstructured":"Wu WC, Yeh PT, Chen SN, Yang CM, Lai CC, Kuo HK (2011) Effects and complications of bevacizumab use in patients with retinopathy of prematurity: a multicenter study in Taiwan. Ophthalmology 118(1):176\u2013183","journal-title":"Ophthalmology."},{"key":"2867_CR16","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00417-007-0661-y","volume":"245","author":"EJ Chung","year":"2007","unstructured":"Chung EJ, Kim JH, Ahn HS, Koh HJ (2007) Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone 1 retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol 245:1727\u20131730","journal-title":"Graefes Arch Clin Exp Ophthalmol."},{"issue":"6","key":"2867_CR17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1097\/IAE.0b013e318177f934","volume":"28","author":"HA Mintz-Hittner","year":"2008","unstructured":"Mintz-Hittner HA, Kuffel RR (2008) Intravitreal injection of bevacizumab (Avastin) for treatment of stage 3 retinopathy of prematurity in zone 1 or posterior zone 2. Retina 28(6):831\u2013838","journal-title":"Retina"},{"key":"2867_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-03","volume":"9","author":"HI Alt\u0131nsoy","year":"2010","unstructured":"Alt\u0131nsoy HI, Mutlu FM, Gungor R, Sarici SU (2010) Combination of laser photocoagulation and intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Ophthalmic Surg Lasers Imaging 9:1\u20135","journal-title":"Ophthalmic Surg Lasers Imaging"},{"issue":"1","key":"2867_CR19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jaapos.2009.10.011","volume":"14","author":"JC Law","year":"2010","unstructured":"Law JC, Recchia FM, Morrison DG, Donahue SP, Estes RL (2010) Intravitreal bevacizumab as adjunctive treatment for retinopathy of prematurity. J AAPOS 14(1):6\u201310","journal-title":"J AAPOS."},{"issue":"7","key":"2867_CR20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","volume":"364","author":"Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group","year":"2011","unstructured":"Mintz-Hittner HA, Kennedy KA, Chuang AZ; BEAT-ROP Cooperative Group (2011) Efficacy of intravitreal bevacizumab (Avastin) for stage 3+ retinopathy of prematurity. N Engl J Med 364(7):603\u2013615","journal-title":"N Engl J Med"},{"issue":"9","key":"2867_CR21","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1007\/s00417-010-1375-0","volume":"248","author":"JY Lee","year":"2010","unstructured":"Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG (2010) Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels. Graefes Arch Clin Exp Ophthalmol 248(9):1257\u20131262","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"12","key":"2867_CR22","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.earlhumdev.2012.09.019","volume":"88","author":"HA Mintz-Hittner","year":"2012","unstructured":"Mintz-Hittner HA (2012) Treatment of retinopathy of prematurity with vascular endothelial growth factor inhibitors. Early Hum Dev 88(12):937\u2013941","journal-title":"Early Hum Dev"},{"issue":"6","key":"2867_CR23","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.ajo.2013.01.014","volume":"155","author":"BC Harder","year":"2013","unstructured":"Harder BC, Schlichtenbrede FC, von Baltz S, Jendritza W, Jendritza B, Jonas JB (2013) Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 155(6):1119\u20131124","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"2867_CR24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1755-3768.2011.02351.x","volume":"91","author":"U Spandau","year":"2013","unstructured":"Spandau U, Tomic Z, Ewald U et al (2013) Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity? Acta Ophthalmol 91(2):170\u2013175","journal-title":"Acta Ophthalmol"},{"issue":"12","key":"2867_CR25","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00417-010-1430-x","volume":"248","author":"H Nazari","year":"2010","unstructured":"Nazari H, Modarres M, Parvaresh MM et al (2010) Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage. Graefes Arch Clin Exp Ophthalmol 248(12):1713\u20131718","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"3","key":"2867_CR26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/IAE.0b013e3181644ad2","volume":"28","author":"GA Lalwani","year":"2008","unstructured":"Lalwani GA, Berrocal AM, Murray TG et al (2008) Off-label use of intravitreal bevacizumab (Avastin) for salvage treatment in progressive threshold retinopathy of prematurity. Retina 28(3):13\u201318","journal-title":"Retina"},{"issue":"1","key":"2867_CR27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1542\/peds.2012-2996","volume":"131","author":"WM Fierson","year":"2013","unstructured":"Fierson WM, American Academy of Pediatrics Section on Ophthalmology, American Academy of Ophthalmology, American Association for Pediatric Ophthalmology and Strabismus, American Association of Certified Orthoptists (2013) Screening examination of premature infants for retinopathy of prematurity. Pediatrics 131(1):189\u2013195, originally published online December 31, 2012. DOI: 10.1542\/peds.2012-2996","journal-title":"Pediatrics"},{"key":"2867_CR28","first-page":"535","volume-title":"Ophthalmology","author":"AH Kashani","year":"2014","unstructured":"Kashani AH, Drenser KA, Capone Jr A (2014) Retinopathy of prematurity. In: Yanoff M, Duker JS (eds) Ophthalmology, 4th Edition. Elsevier Saunders, pp 535\u2013540","edition":"4"},{"key":"2867_CR29","unstructured":"http:\/\/www.turkstat.gov.tr\/PreHaberBultenleri.do;jsessionid=PJhDTnPKfGBrjQQGqRstp6NpTt9GpvCTMBFGL1 mQJqnr2QWJp2FJ!-568420742?id\u2009=\u200916048 Accessed 20 Aug 2014"},{"issue":"9832","key":"2867_CR30","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1016\/S0140-6736(12)60820-4","volume":"379","author":"H Blencowe","year":"2012","unstructured":"Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R, Adler A, Vera Garcia C, Rohde S, Say L, Lawn JE (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162\u20132172","journal-title":"Lancet"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2867-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00417-014-2867-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-014-2867-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,30]],"date-time":"2023-07-30T17:18:13Z","timestamp":1690737493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00417-014-2867-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,14]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["2867"],"URL":"https:\/\/doi.org\/10.1007\/s00417-014-2867-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,14]]}}}